

SECTION 1: IDENTIFICATION

Manufacturer Name and Address: Medefil, Inc.

250 Windy Point Drive

Glendale Heights, Illinois 60139

USA

Emergency Telephone Number: Tel: (630) 682 - 4600

Fax: (630) 681 - 9100

Product Name: Heparin I. V. Flush Syringe, USP

SECTION 2: HAZARD(S) IDENTIFICATION

Emergency Overview

Heparin I. V. Flush Syringe, USP, is a saline solution containing heparin sodium, a heterogeneous group of straight-chain anionic mucopolysaccharides called glycosaminoglycans, having anticoagulant properties.

U.S. OSHA GHS Classification

Physical Hazards

Hazard Class Not Classified Hazard Category Not Classified

Health Hazards

Hazard Class Not Classified Hazard Category Not Classified

Label Element(s)

Pictogram NA Signal Word NA Hazard Statement(s) NA

Precautionary Statement(s)

Prevention Do not breathe vapor or spray.

Wash hands thoroughly after handling.

Response Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. If eye irritation

persists, get medical attention.



3. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name: Heparin Sodium, USP

Chemical Formula: Heparin is an acidic, polymeric mucopolysaccharide composed of units

of glucuronic acid and sulfated glucosamine.

Component: Heparin Sodium

Approximate Percent

 by Weight:
 < 0.1%</td>

 CAS Number:
 9041-08-1

 RTECS Number:
 MI0850000

The other ingredients include water for injection (WFI), less than 1% include sodium chloride and hydrochloric acid; sodium hydroxide is used to adjust the pH.

4. FIRST AID MEASURES

Eye Contact

Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention.

Skin Contact

Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention.

Inhalation

Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Ingestion

Remove from source of exposure. If signs of toxicity occur, seek medical attention.

5. FIRE FIGHTING MEASURES

Flammability

None anticipated for this aqueous product.

Fire and Explosion Hazard

None anticipated for this aqueous product.

Extinguishing Media

No special provisions required. As with any fire, use extinguishing media appropriate for the primary cause of the fire such as carbon dioxide, dry chemical extinguishing powder or foam.

Special Fire Fighting Procedures

No special provisions required. As with any fire, use normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.



6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal

Isolate area around the spill. Put on suitable protective clothing and/or equipment to avoid personal contact. Remove the liquid with suitable material and clean affected area with soap and water. Care should be taken to avoid environmental release.

7. HANDLING AND STORAGE

Handling

No special handling required for hazard control under conditions of normal product use.

Storage

No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label or the product package insert.

Special Precautions

No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

	Exposure Limits					
Component	OSHA-PEL	ACGIH-TLV	AIHA WEEL			
Heparin Sodium	8-hr TWA: Not	8-hr TWA: Not	8-hr TWA: Not			
	Established	Established	Established			

Notes:

OSHA-PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit.

ACGIH-TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.

AIHA WEEL: American Industrial Hygiene Association Workplace Environmental Exposure Level.

EEL: Employee Exposure Limit. TWA: Time Weighted Average.

Respiratory Protection

Respiratory protection is normally not needed during intended product use. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor sufficient to control exposures to below the occupational Exposure Level (OEL).

Skin Protection

If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye Protection

Eye protection is normally not required during the intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls

Engineering controls are normally not needed during the normal use of this product.



9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State Clear, colorless to practically colorless liquid

Odor NA Odor Threshold NA 5.0 to 7.5 рH Melting Point/Freezing Point NA Initial Boiling Point/Boiling Point Range NA **Evaporation Rate** NA Upper/Lower Flammability or Explosive Limits NA Vapor Pressure and Density (Air =1) NA Solubility NA Partition Coefficient: n-octanol/water NA Auto-ignition Temperature NA **Decomposition Temperature** NA

10. STABILITY AND REACTIVITY

Reactivity Not determined

Chemical Stability Stable under standard use and labeled storage conditions.

Hazardous Reactions
Conditions to Avoid
Incompatibilities
Not determined
Not determined
Not determined
Not determined
Not determined

Hazardous Polymerization Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of	Value	Units	Species
			Administration			
Heparin Sodium	100	LD50	Oral	>5770	mg/kg	Rat
				>5000	mg/kg	Mouse
Heparin Sodium	100	LD50	Intravenous	2902	mg/kg	Rat
				2800	mg/kg	Mouse
				1000	mg/kg	Dog
Heparin Sodium	100	LD50	Intraperitoneal	>2500	mg/kg	Mouse

LD50: Dosage that produces 50% mortality.

Occupational Exposure Potential

Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms



None anticipated from the normal handling of this product.

Dermal or Respiratory Sensitization

None anticipated from the normal handling of this product.

Mutagenicity

Studies to evaluate the genotoxic potential of heparin have not been conducted.

Carcinogenicity

Studies to evaluate the effects of heparin on fertility or fetal development have not been conducted in animals.

Carcinogen Lists

IARC: Not listed NTP: Not listed OSHA: Not listed

Specific Target Organ Toxicity (Single Exposure)

NA

Specific Target Organ Toxicity (Repeat Exposure)

Based on clinical use, possible target organs include the blood and liver.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity

Persistence/Biodegradability

Bioaccumulation

Mobility in Soil

Not determined for product.

Not determined for product.

Not determined for product.

Not determined for product.

13. DISPOSAL CONSIDERATIONS

Waste Disposal All waste materials must be properly characterized. Further,

disposal should be performed in accordance with the federal,

state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with

federal, state and local regulations.

14. TRANSPORTATION INFORMATION

DOT Shipping Name Not regulated.
DOT UN Number Not regulated.

15. REGULATORY INFORMATION

This safety datasheet complies with the requirements of EC Regulation No. 1907/2006.





State Right To Know Refer to the applicable state to determine applicability.

US TSCA Status Exempt. However, heparin sodium is listed on the TSCA

inventory.

Canada DSL Heparin Sodium is listed on the DSL.

EU Classification Medicinal products are exempt from the requirements of the EU

Dangerous Preparations Directive.

16. OTHER INFORMATION

Refer to Medefil, Inc. prescribing information for further information at http://www.medefilinc.com

CAS: Chemical Abstracts Service Number

DSL: Domestic Substances List DOT: Department of Transportation

EU: European Union

IARC: International Agency for Research on Cancer

LD: Lethal Dose

NTP: National Toxicology Program

OSHA: Occupational Safety and Health Agency

TSCA: Toxic Substances Control Act

The above information is believed to be accurate and represents the best information currently available to Medefil, Inc. The information has not been verified and we cannot, therefore, guarantee its accuracy or completeness or adequacy for all persons and situations or as to the results to be obtained by use of the information. It is the user's obligation to evaluate and use this product safely and to comply with all applicable laws and regulations.

Users should make their own investigations to determine the suitability of the information for their own particular purposes. The user assumes all risks from use of the product. In no event shall Medefil, Inc. be liable for any claims, losses or damages of any third party, or for lost profits, or for any special, indirect, incidental, consequential or exemplary damages however arising, even if Medefil, Inc. has been advised of the possibility of such damages.

WE MAKE NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, WITH RESPECT TO SUCH INFORMATION AND WE ASSUME NO LIABILITY RESULTING FROM ITS USE.